Wave Life Sciences Ltd. Ordinary Shares

Day range

$3.13 – $3.24

Open

$3.17

Prev close

$3.18

Volume

1.59M

Market cap

$626.61M

Shares out

197.05M

P/E

—

P/S

9.59

P/B

1.38

P/FCF

—

ROE

-44.6%

ROA

-36.3%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Investor presentationJul 30, 2026

  On July 30, 2026, the Company updated its corporate presentation, which is available on the "Investors" section of the Company's website at http://ir.wavelifesciences.com/. This presentation is also furnished as Exhibit 99.2 to this Current Report on Form 8-K

• Special meeting resultsJun 26, 2026

  Scheme Shareholders, comprised of holders of Wave-Singapore ordinary shares (other than CEDE & Co.) in the registers of Wave-Singapore and The Depository Trust Company as of the record date, voted in favor of the Wave Redomiciliation Proposal and approved the Scheme of Arrangement in accordance with Singapore law and order of the Singapore High Court. The final voting results are described below.

• Investor presentationMay 18, 2026

  Wave management will host an investor conference call at 5:30 p.m. ET on May 18, 2026, to review the RestorAATion-2 program and updated clinical data. For purposes of the call, and in connection with the announcement described above, the Company plans to share an investor slide presentation during the investor conference call, which will be available on the "Investors" section of the Company's website.

• Investor presentationApr 28, 2026

  On April 28, 2026, the Company updated its corporate presentation, which is available on the "Investors" section of the Company's website at http://ir.wavelifesciences.com/. This presentation is also furnished as Exhibit 99.2 to this Current Report on Form 8-K

• Merger agreementApr 15, 2026

  The boards of directors of each of Wave-Singapore and Wave Life Sciences, Inc., a Delaware corporation ('Wave-Delaware'), approved the entry by Wave-Singapore and Wave-Delaware, respectively, into an Implementation Agreement (the 'Implementation Agreement'). The Implementation Agreement was executed by Wave-Singapore and Wave-Delaware on April 15, 2026 and provides for a statutory procedure known as a scheme of arrangement (the 'Scheme of Arrangement') to be implemented by Wave-Singapore and Wave-Delaware under Singapore law, subject to approval of the shareholders of Wave-Singapore and the High Court of the Republic of Singapore. Pursuant to the Scheme of Arrangement, all issued ordinary shares in the capital of Wave-Singapore (the 'Wave-Singapore Ordinary Shares') as of immediately prior to the effective time of the Scheme of Arrangement will be exchanged on a one-for-one basis for newly issued shares of common stock of Wave-Delaware, and Wave-Singapore will become a subsidiary of Wave-Delaware.

Days to cover

5.7

Short interest

18.56M

Avg volume

3.26M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Analysts Estimate GSK (GSK) to Report a Decline in Earnings: What to Look Out for
  negativeZacks Investment Research· Oct 21, 2026
• Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight
  positiveGlobeNewswire Inc.· Oct 15, 2026
• Oligonucleotides Clinical Trial Drug Development Pipeline Expands with Contributions from 200+ Key Companies | DelveInsight
  positiveGlobeNewswire Inc.· May 14, 2026
• Wave Life Sciences Reclaims Rare Disease Drug From GSK, Targets Faster FDA Path
  positiveBenzinga· Feb 2, 2026
• Golden Cross Alert: 3 Stocks With Major Upside Potential
  positiveInvesting.com· Dec 11, 2025